St. Paul, Minn.-based Cardiovascular Systems said that the first patient has already been treated with the device in Hong Kong.
“Orbital Atherectomy is simple to use. It is a very controllable and predictable atherectomy device and is especially useful for diffuse and severely calcified coronary arteries, ensuring the angioplasty procedures can be completed with ease and good results. OAS also helps to fill the gap of the conventional devices when treating calcified coronary arteries,” Dr. Michael Kang-Yin Lee of Hong Kong’s Queen Elizabeth Hospital said in a prepared release.
Cardiovascular Systems said it originally inked the exclusive international distribution agreement with OrbusNeich in July this year, after having announced in January that it would serve as the exclusive U.S. distributor for OrbusNeich.
“I was very pleased to have witnessed the first ever coronary orbital atherectomy procedure performed in Hong Kong. CSI’s device supports our key business focus of providing solutions for all complex vascular interventions. We look forward to continuing global distribution of this clinically proven technology to our customers,” OrbusNeich founder & chairman emeritus Teddy Chien said in a press release.
“We are thrilled to begin introducing our proven coronary atherectomy technology to physicians worldwide. As our international distribution partner, OrbusNeich, identifies new markets, we are prepared to provide best-in-class training to physicians committed to improving patient outcomes within this underserved patient population,” prez & CEO Scott Ward said in prepared remarks.
Last month, Cardiovascular Systems released fiscal year 2019 first quarter earnings that beat sales consensus on Wall Street but missed expectations for losses per share for the quarter.
The post Cardiovascular Systems enters Chinese market through OrbusNeich deal appeared first on MassDevice.